New shield for chemo patients: can trilaciclib prevent dangerous side effects?
NCT ID NCT07490236
First seen Mar 29, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study looks at whether a drug called trilaciclib can protect the bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe drops in blood cells, which can be dangerous and delay treatment. About 100 adults will take part, first by reviewing past data, then by testing the drug in a planned way. Researchers hope to create a model to predict who will benefit most from this protective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRILACICLIB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050300, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.